Researchers from the Life and Health Sciences Research Institute of the University of Minho have developed a more timeless, accurate and less expensive technique for diagnosing Acute Myeloid Leukemia (AML). The invention relates to sequences of oligonucleotides that enable the detection of multiple mutations in genes relevant to the diagnosis, classification and therapeutics of AML.
The present invention provides the sequence of primers for AML-associated genes which will be used to develop a chip for classifying AML subtypes, diagnosing AML and developing personalised therapy. The design of these sequences allows for the identification of mutations in genes underlying the development of AML, leading to faster diagnosis and classification of different AML subtypes. Moreover, this more efficient diagnosis enables the selection of specific personalized therapies for each AML patient.
Innovative Aspects and Main advantages
The design of these primer sequences enables faster diagnosis and classification of different AML subtypes. Additionally, this more efficient diagnosis allows for the selection of specific personalised therapies for each AML patient.
There is an urgent need to develop new sensitive and rapid tools for the early diagnosis of AML, enabling personalized treatment of patients. Next-generation sequencing (NGS) analysis is still associated with a high financial burden due to expensive technical equipment and staff. Moreover, the sensitivity and accuracy of NGS need improvement, and its long turnaround time limits the timely allocation of AML patients to the right treatment. With our methodology, we are implementing a new concept that generates similar data as NGS but is more timeless and less expensive. These primer sequences enable the development of new strategies that reduce the time for patient diagnosis, resulting in more efficient personalized therapy selection. The described invention could be combined with microdevices for the early and low-cost diagnosis of AML, treatment selection, and monitoring of treatment efficiency.
Stage of Development
Proof of concerto. The in silico design is completed.
Intellectual Property Rights
We intend to file a patent for the technology.
The team is looking for companies willing to discuss research collaborations or/and licensing arrangements for commercial exploitation of the technology.